HDAC2
ENSG00000196591
Target class
Epigenetic regulator
Chromosome
6
Approved drugs
5
Clinical candidates (approved and in development)
12
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 12
- Chemical probe available
- Yes
- Target name
- HDAC2
- Gene name
- Histone deacetylase 2
- Gene symbol
- HDAC2
- Protein name
- Histone deacetylase 2 (HD2) (EC 3.5.1.98) (Protein deacylase HDAC2) (EC 3.5.1.-)
- RPD3
- YAF1
- KDAC2
- Gene biotype
- Protein coding
- Gene family
- Histone deacetylases, class I|EMSY complex|NuRD complex subunits|SIN3 histone deacetylase complex subunits|CoREST complex subunits|MiDAC complex subunits|MIER complex subunits|RERE complex subunits
- Target class
- Epigenetic regulator
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 27.78
- Tissue specificity (Gini)
- 0.249
- Tissue specificity (tau)
- 0.533
- KEGG gene identifiers
- hsa:3066
- Protein interaction confidence
- 0.87486
- Protein interaction partners
- 235
- R-HSA-193670
- R-HSA-2122947
- R-HSA-2644606
- R-HSA-2894862
- R-HSA-3214815
- R-HSA-350054
- R-HSA-427389
- R-HSA-427413
- R-HSA-4551638
- R-HSA-6804758
- R-HSA-73762
- R-HSA-8943724
- R-HSA-9022692
- R-HSA-9022699
- R-HSA-9615017
- R-HSA-9619665
- R-HSA-9679191
- R-HSA-9701898
- R-HSA-9764725
- R-HSA-983231
- R-HSA-9843940
- R-HSA-9844594
- R-HSA-9845323
- R-HSA-9937850
- R-HSA-9940951
And 1 more, listed on the interactive page.
- End position
- 114011308
- Start position
- 113933028
- Chromosome
- 6
- Strand
- Reverse
- Nucleus . Cytoplasm .
- Nucleoplasm
- PubMed 20523938
- PubMed 24970816
- PubMed 28977666
- PubMed 33283408
- Tissue specificity (tau)
- 0.533192
- Expression inequality (Gini)
- 0.248821
Expression in transcripts per million
- Testis
- 27.78
- Cells - Cultured fibroblasts
- 26.15
- Cells - EBV-transformed lymphocytes
- 25.97
- Uterus
- 22.59
- Cervix - Endocervix
- 22.18
Expression in transcripts per million
- Testis27.78
- Cells - Cultured fibroblasts26.15
- Cells - EBV-transformed lymphocytes25.97
- Uterus22.59
- Cervix - Endocervix22.18
- Ovary22.09
- Cervix - Ectocervix20.11
- Brain - Cerebellar Hemisphere19.33
- Artery - Tibial19.32
- Fallopian Tube19.27
- Nerve - Tibial17.64
- Vagina17.18
- Artery - Aorta16.5
- Bladder16.17
- Colon - Sigmoid16.02
- Pituitary15.71
- Artery - Coronary15.55
- Skin - Sun Exposed (Lower leg)15.03
- Skin - Not Sun Exposed (Suprapubic)14.87
- Thyroid14.79
- Esophagus - Mucosa14.6
- Lung14.55
- Brain - Cerebellum14.3
- Breast - Mammary Tissue14.13
- Adipose - Subcutaneous13.73
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0006338
- GO:0008284
- GO:0031507
- GO:0033148
- GO:0045862
- GO:0045944
- GO:0050847
- GO:0000118
- GO:0000781
- GO:0000785
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0016581
- GO:0032991
- GO:0035098
- GO:0070822
- GO:0001221
- GO:0003723
- GO:0004407
- GO:0005515
- GO:0019899
- GO:0031492
- GO:0033558
- GO:0042393
- GO:0042826
- GO:0051059
- GO:0061629
- GO:0141221
- GO:0160008
- GO:0160009
- GO:0160010
- GO:0160216
Related records
Trials (805)
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
- A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
- A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
- A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
- A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
- A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
- A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
- A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
- A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
- A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
- A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
- A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
- A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.
- A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
- A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
- A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
- A Panobinostat Presurgery
Drugs (14)
- Abexinostat Histone deacetylase inhibitor
- Belinostat Histone deacetylase inhibitor
- CUDC-101 Histone deacetylase inhibitor
- Entinostat Histone deacetylase inhibitor
- Fimepinostat Histone deacetylase inhibitor
- Givinostat Histone deacetylase inhibitor
- Givinostat hydrochloride Histone deacetylase inhibitor
- Mocetinostat Histone deacetylase 2 inhibitor
- Panobinostat Histone deacetylase inhibitor
- Panobinostat lactate Histone deacetylase inhibitor
- Quisinostat Histone deacetylase inhibitor
- Romidepsin Histone deacetylase inhibitor
- Tacedinaline Histone deacetylase inhibitor
- Vorinostat Histone deacetylase 2 inhibitor